Table 3 GRADE summary of results for secondary outcomes
Outcomes | Odds ratio (95% CI) | Sample size | No. of studies (total patients) | Certainty (GRADE) | |
|---|---|---|---|---|---|
Vitamin C | Control | ||||
Short-term mortality | 0.89 (0.77 to 1.04) | 507/1682 | 546/1682 | 18Â (3364) | Moderate |
Dose—< 25 mg/kg/d | – | – | – | 0 (0) | – |
Dose—25–100 mg/kg/d | 0.80 (0.65 to 0.97) | 256/966 | 297/961 | 15 (1927) | High |
Dose—> 100 mg/kg/d | 1.02 (0.82 to 1.27) | 251/716 | 249/721 | 3 (1437) | Low |
Therapy regimens—combined therapy | 0.95 (0.78 to 1.16) | 288/994 | 296/992 | 11 (1986) | Moderate |
Therapy regimens—monotherapy | 0.82 (0.66 to 1.03) | 219/688 | 250/690 | 7 (1378) | Low |
Duration—< 96 h | 0.72 (0.33 to 1.58) | 13/67 | 18/72 | 2 (139) | Very low |
Duration—96 h | 1 (0.79 to 1.27) | 208/631 | 210/639 | 5 (1270) | Low |
Duration—Unclear | 0.84 (0.69 to 1.02) | 286/984 | 318/971 | 11 (1955) | Moderate |
Patient—sepsis | 0.43 (0.2 to 0.96) | 15/61 | 24/56 | 1 (117) | Moderate |
Patient—septic shock | 0.9 (0.71 to 1.13) | 214/678 | 230/682 | 10 (1360) | Moderate |
Patient—unclear | 0.93 (0.77 to 1.14) | 278/943 | 292/944 | 7 (1887) | Moderate |
Duration of vasopressor use | − 15.07 (− 21.59 to − 8.55) | 387 | 385 | 10 (772) | Moderate |
IV vitamin C level | 353.59 (91.19 to 615.99) | 218 | 221 | 5Â (439) | Low |
Adverse events | 1.98 (1.06 to 3.68) | 307/1275 | 242/1280 | 9Â (2555) | Moderate |